88 related articles for article (PubMed ID: 22763829)
1. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.
Yasuda S; Tsuchiya I; Okada K; Tanaka A; Suzuki T; Sadahiro S; Takeda K; Yamamoto S; Nakui M
Tokai J Exp Clin Med; 2012 Jul; 37(2):57-61. PubMed ID: 22763829
[TBL] [Abstract][Full Text] [Related]
2. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: two case reports.
Imaoka Y; Kuranishi F; Miyazaki T; Yasuda H; Ohno T
World J Surg Oncol; 2017 Sep; 15(1):170. PubMed ID: 28893260
[TBL] [Abstract][Full Text] [Related]
10. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
11. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
[TBL] [Abstract][Full Text] [Related]
13. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
Ahn E; Kim H; Han KT; Sin JI
Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.
Hayashi H; Kurata T; Fujisaka Y; Kawakami H; Tanaka K; Okabe T; Takeda M; Satoh T; Yoshida K; Tsunoda T; Arao T; Nishio K; Nakagawa K
Cancer Sci; 2013 Jan; 104(1):98-104. PubMed ID: 23020774
[TBL] [Abstract][Full Text] [Related]
16. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
18. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
[TBL] [Abstract][Full Text] [Related]
19. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
Nair SK; Morse M; Boczkowski D; Cumming RI; Vasovic L; Gilboa E; Lyerly HK
Ann Surg; 2002 Apr; 235(4):540-9. PubMed ID: 11923611
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Sugiura F; Inoue K; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]